Sales for this month
February 2026Fiscal year ending March 2026Monthly results for the key figures are provided, but there is no commentary on changes during the month.
Disclosed around the middle of each month or later. Figures for June, September, December, and March are disclosed on the same day as the announcement of the quarterly results for each period.
Monthly figures for the previous year are also provided for net premiums written, the number of policies in force, the average retention rate, the number of applications for Doubutsu Kenkatsu, and the number of patents held.
Scope of aggregation: The Group's pet insurance business and synergy-creation businesses
| Item | Details |
|---|---|
| Month Covered | February 2026 |
| Fiscal Year Covered | Fiscal year ending March 2026 |
| Scope of aggregation | The Group's pet insurance business and synergy-creation businesses |
| Key KPIs | Indicator name Net Premiums Written / Value ¥5,307 million / Year on year ¥106.7 million, Indicator name Number of in-force policies / Value 1,387,367 Engagements / Year on year 108.5 Engagements, Indicator name Average renewal rate / Value 88.7 ％ / Year on year 0.4 ％, Indicator name Doubutsu Kenkatsu program (gut flora testing) applications / Value 20,880 Engagements / Year on year 101.2 Engagements, Indicator name Patents held / Value 25 Engagements / Year on year 113.6 Engagements |
| Monthly Commentary | Monthly results for the key figures are provided, but there is no commentary on changes during the month. |
| Monthly trend for the same period last year | Monthly figures for the previous year are also provided for net premiums written, the number of policies in force, the average retention rate, the number of applications for Doubutsu Kenkatsu, and the number of patents held. |
| Next Scheduled Disclosure | Disclosed around the middle of each month or later. Figures for June, September, December, and March are disclosed on the same day as the announcement of the quarterly results for each period. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company has not explained the specific reasons for changes in the monthly figures. It states that the number of patents held is disclosed as a key metric related to the promotion of Bio Insurtech toward realizing a preventive insurance company.